University of L'Aquila, L'Aquila, Italy.
Clin Gastroenterol Hepatol. 2019 Apr;17(5):809-817. doi: 10.1016/j.cgh.2018.01.018. Epub 2018 Mar 14.
BACKGROUND & AIMS: This narrative review provides an overview of the current regulation of probiotics, with a focus on those used for the dietary management of medical conditions (Medical Foods).
The probiotic market has grown rapidly, both for foods and supplements intended to enhance wellness in healthy individuals, and for preparations for the dietary management of disease. Regulation of probiotics varies between regions. Unless they make specific disease-related health claims, probiotics are regulated as food supplements and regulation is focused on the legitimacy of any claims, rather than efficacy, safety and quality. Many properties of probiotics are strain-specific, and safety and efficacy findings associated to specific formulations should not be generalized to other probiotic products. Manufacturing processes, conditions and ingredients are important determinants of product characteristics and changes to manufacturing are likely to give rise to a product not identical to the "original" in efficacy and safety if proper measures and controls are not taken. Current trademark law and the lack of stringent regulation of probiotic manufacturing mean that the trademark owner can commercialize any formulation under the same brand, even if significantly different from the original. These regulatory deficits may have serious consequences for patients where probiotics are used as part of clinical guideline-recommended management of serious conditions such as inflammatory bowel diseases, and may make doctors liable for prescribing a formulation not previously tested for safety and efficacy.
Current regulation of probiotics is inadequate to protect consumers and doctors, especially when probiotics are aimed at the dietary management of serious conditions.
本综述概述了益生菌的现行法规,重点介绍了用于医疗条件(医用食品)饮食管理的益生菌。
益生菌市场增长迅速,无论是用于增强健康个体健康的食品和补充剂,还是用于疾病饮食管理的制剂。益生菌的监管因地区而异。除非它们有特定的与疾病相关的健康声明,否则益生菌被监管为食品补充剂,监管重点是任何声明的合法性,而不是功效、安全性和质量。许多益生菌的特性是菌株特异性的,与特定配方相关的安全性和功效发现不应推广到其他益生菌产品。制造工艺、条件和成分是产品特性的重要决定因素,如果没有采取适当的措施和控制,制造过程的改变可能会导致产品在功效和安全性方面与“原始”产品不同。当前的商标法和对益生菌制造的严格监管缺乏意味着商标所有者可以在同一品牌下商业化任何配方,即使与原始配方有很大的不同。这些监管缺陷可能会对患者造成严重后果,因为益生菌被用作炎症性肠病等严重疾病临床指南推荐管理的一部分,并且可能会使医生因开处方未经安全性和功效测试的配方而承担责任。
现行的益生菌监管法规不足以保护消费者和医生,尤其是当益生菌旨在用于严重疾病的饮食管理时。